Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivmecillinam with amoxicillin/clavulanic acid for step-down oral therapy in febrile ESBL-producing Enterobacterales UTIs
2020-005738-13Phase 4Active
- Sponsor
- Region Skåne
- Start
- Dec 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of pivmecillinam, amoxicillin + clavulanate, trimethoprim + sulfamethoxazole and ciprofloxacin in urinary tract infection (UTI) and infections due to extended-spectrum beta-lactamase-producing Enterobacterales (2 arms), sponsored by Region Skåne. Primary endpoint: Microbiological cure at test-of-cure. Started Dec 2020; status: active.
02
Drugs
pivmecillinamamoxicillin + clavulanatetrimethoprim + sulfamethoxazoleciprofloxacin
03
Conditions
urinary tract infection (UTI)infections due to extended-spectrum beta-lactamase-producing Enterobacterales
Beyond the preview
Go deeper on 2020-005738-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005738-13.